Revance Company Insiders

RVNC Stock  USD 3.40  0.11  3.34%   
About 91 percent of Revance's insiders are activelly selling. The analysis of insiders' sentiment of trading Revance stock suggests that quite a large number of insiders are panicking at this time. Revance employs about 597 people. The company is managed by 40 executives with a total tenure of roughly 207 years, averaging almost 5.0 years of service per executive, having 14.93 employees per reported executive.
Mark Foley  CEO
CEO Director
Dan Browne  CEO
Co-Founder and Presidentident, CEO, Board Member

Revance's Insider Buying Vs Selling

9

 
Selling
 
Buying

Latest Trades

2024-04-16Erica JordanDisposed 2392 @ 3.8View
2024-03-18Tobin SchilkeDisposed 9361 @ 5.04View
2023-10-04Thomas R. CarperAcquired @ 10.55
2023-09-05Dwight MoxieDisposed 23853 @ 17.81View
2023-08-03Mark J FoleyDisposed 26279 @ 22.57View
2023-07-03Mark J FoleyDisposed 26279 @ 24.94View
2023-06-15Carey Oconnor KolajaDisposed 2500 @ 28.24View
2023-06-09Dustin S SjutsDisposed 5000 @ 30.82View
2023-06-01Tobin SchilkeDisposed 2701 @ 30.57View
2023-05-15Mark J FoleyDisposed 70447 @ 34.55View
2023-05-01Tobin SchilkeDisposed 3201 @ 31.7View
Monitoring Revance's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Revance's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Revance. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Revance's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revance. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.

Revance's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Revance's future performance. Based on our forecasts, it is anticipated that Revance will maintain a workforce of about 600 employees by May 2024.
 
Yuan Drop
 
Covid

Revance's latest congressional trading

Congressional trading in companies like Revance, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Revance by those in governmental positions are based on the same information available to the general public.
2023-10-04Senator Thomas R CarperAcquired Under $15KVerify

Revance Management Team Effectiveness

The company has return on total asset (ROA) of (0.2602) % which means that it has lost $0.2602 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance's management efficiency ratios could be used to measure how well Revance manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.24, whereas Return On Tangible Assets are forecasted to decline to (0.73). At present, Revance's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 11.7 M, whereas Total Assets are forecasted to decline to about 331.9 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 88.8 M, whereas Net Loss is projected to grow to (304.7 M).

Revance Workforce Comparison

Revance is rated third in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 4,641. Revance retains roughly 597 in number of employees claiming about 13% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.73) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.73.

Revance Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revance insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revance's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Revance insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.9091
10
11
 1,692,119 
 106,957 
2023-12-01
3.0
3
1
 962.00 
 4,712 
2023-09-01
0.4444
4
9
 186,729 
 166,884 
2023-06-01
1.5
18
12
 63,538 
 185,146 
2023-03-01
0.3125
5
16
 151,235 
 164,242 
2022-12-01
1.0
3
3
 1,855 
 53,747 
2022-03-01
0.6667
8
12
 649,298 
 25,012 
2021-12-01
1.6667
5
3
 112,724 
 44,165 
2021-06-01
8.5
17
2
 63,914 
 413.00 
2021-03-01
1.6
16
10
 428,088 
 80,388 
2020-12-01
0.3333
2
6
 841.00 
 167,581 
2020-09-01
1.8571
13
7
 2,067,631 
 199,503 
2020-06-01
16.0
16
1
 127,763 
 432.00 
2020-03-01
1.5
9
6
 800,500 
 10,848 
2019-12-01
0.5556
5
9
 941,268 
 73,103 
2019-06-01
17.0
17
1
 110,923 
 1,383 
2019-03-01
0.8
12
15
 448,191 
 36,887 
2018-12-01
0.8333
5
6
 121,381 
 16,479 
2018-06-01
4.5
18
4
 190,811 
 18,062 
2018-03-01
1.0556
19
18
 505,841 
 124,101 
2017-12-01
0.8571
6
7
 48,076 
 67,161 
2017-09-01
1.6667
5
3
 148,331 
 30,731 
2017-06-01
2.8333
17
6
 91,904 
 70,093 
2017-03-01
1.0
6
6
 342,900 
 28,540 
2016-12-01
0.4
2
5
 37,000 
 39,229 
2016-09-01
2.0
2
1
 18,666 
 666.00 
2016-06-01
1.2222
11
9
 59,749 
 21,123 
2016-03-01
1.1818
13
11
 353,998 
 30,158 
2015-12-01
0.625
5
8
 253,271 
 21,796 
2015-09-01
0.2727
3
11
 6,000 
 15,699 
2015-06-01
1.0526
20
19
 106,133 
 35,219 
2015-03-01
1.2667
19
15
 480,623 
 10,000 
2014-12-01
0.7273
8
11
 11,480 
 9,000 
2014-09-01
0.5263
10
19
 233,374 
 195,587 
2014-03-01
0.6271
37
59
 18,778,675 
 11,576,473 

Revance Notable Stakeholders

A Revance stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Revance often face trade-offs trying to please all of them. Revance's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Revance's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark FoleyCEO DirectorProfile
Dan BrowneCo-Founder and Presidentident, CEO, Board MemberProfile
Daniel BrowneCo-Founder and Presidentident, CEO, DirectorProfile
Angus RussellChairman of the BoardProfile
Ben PutmanVice President - DigitalProfile
Caryn McDowellSenior Vice President General Counsel, and Corporate SecretaryProfile
Lauren SilvernailCFO, Executive Vice President of Corporate DevelopmentProfile
Sharon HallVice President of Regulatory AffairsProfile
Todd ZavodnickChief Commercial Officer and President Aesthetics & TherapeuticsProfile
Erica BazerkanianVice President of MarketingProfile
Dustin SjutsVice President of Strategy and SalesProfile
Taryn ConwayVice President of MarketingProfile
Tobin SchilkeCFO and Principal Financial OfficerProfile
Abhay JoshiCOOProfile
Curtis RueggExecutive VP of RandD and Technical OperationsProfile
Jill BeraudDirectorProfile
Jeanie HerbertSr. Director of Investor RelationsProfile
Philip VickersIndependent DirectorProfile
Julian GangolliDirectorProfile
Robert ByrnesIndependent DirectorProfile
Ron WootenIndependent DirectorProfile
Phil VickersDirectorProfile
Ronald WootenIndependent DirectorProfile
Marc KorenbergSenior Director - Commercial OperationsProfile
Mark PrygockiDirectorProfile
Chris NoletDirectorProfile
Cyril AllouchePrincipal Financial Officer and Principal Accounting OfficerProfile
Phyllis GardnerBoard MemberProfile
Jonathan TunnicliffeBoard MemberProfile
Erica JordanChief OfficerProfile
Dwight MoxieChief CounselProfile
Justin FordVP PeopleProfile
Jim GlasheenBoard MemberProfile
Jessica SerraHead ESGProfile
Ronald EastmanBoard MemberProfile
Aubrey RankinConsultantProfile
Conor GallagherHead AestheticsProfile
Azita NejadVP OperationsProfile
Amie KrauseChief OfficerProfile
MD MBAChief OfficerProfile

About Revance Management Performance

The success or failure of an entity such as Revance often depends on how effective the management is. Revance management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Revance management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Revance management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.69)(0.73)
Return On Capital Employed(0.57)(0.60)
Return On Assets(0.68)(0.71)
Return On Equity 2.14  2.24 
The data published in Revance's official financial statements usually reflect Revance's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Revance. For example, before you start analyzing numbers published by Revance accountants, it's critical to develop an understanding of what Revance's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Revance's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revance's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Revance's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Revance. Please utilize our Beneish M Score to check the likelihood of Revance's management manipulating its earnings.

Revance Workforce Analysis

Traditionally, organizations such as Revance use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Revance within its industry.

Revance Manpower Efficiency

Return on Revance Manpower

Revenue Per Employee392K
Revenue Per Executive5.9M
Net Loss Per Employee542.7K
Net Loss Per Executive8.1M
Working Capital Per Employee418.2K
Working Capital Per Executive6.2M
When determining whether Revance offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Revance's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Revance Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Revance Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revance. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Revance Stock analysis

When running Revance's price analysis, check to measure Revance's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revance is operating at the current time. Most of Revance's value examination focuses on studying past and present price action to predict the probability of Revance's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revance's price. Additionally, you may evaluate how the addition of Revance to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Revance's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.83)
Revenue Per Share
2.766
Quarterly Revenue Growth
0.398
Return On Assets
(0.26)
Return On Equity
(20.97)
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.